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Basophils are an infrequent typeofleukocytethat bear high affinity IgE receptors,
contain important amounts ofhistamine in their granules, and are capableofgener-
ating high levels ofsulfidoleukotrienes. They are activated afterIgE receptor cross-
linking, and their products lead to the well-known signs ofimmediate-type hyper-
sensitivity (1). Basophils are also activated by IgE-independent mechanisms, and
may thus contribute to nonallergic inflammatory responses. So far two well-defined
chemotactic peptides, the anaphylatoxin C5a and the bacterial product analogue
FMLP, have been shown to induce basophil degranulation (1, 2). In addition, sev-
eralcell-derived factors have been repeatedlyimplicated in basophil activation. How-
ever, upto nowno defined andpure cytokine was foundtohave apotent and consis-
tent histamine-releasing activity forbasophilsincubated inphysiological buffers(3, 4).
NAF/NAP-1 is a novel neutrophil-activating peptide that was originally isolated
from theculturefluids ofstimulated human monocytes (5-7), andwas subsequently
shown to be produced by a variety ofdifferent cells (reviewed in reference 8). Like
C5a and FMLP, NAF/NAP-1 activates human neutrophils, inducing chemotaxis,
shape change, granule release, and the respiratory burst (8). In this paper we show
that NAF/NAP-1 induces the release ofhistamine and leukotriene C4 (LTC4) from
human basophils that have been exposed to IL-3. Our results indicate that in the
presence of IL-3, NAF/NAP-1 fulfills the role ofa "histamine-releasing factor" and
may thus mediate IgE-independent hypersensitivity reactions.
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Materials and Methods
BriefDefinitive Report
Mediator Releasefrom Human Basophils.
￿
Blood collection, cell isolation, and the mediator
releaseassays were performed exactly as described (9). The mononuclearcell fractionscon-
taining the basophils were suspended at a cell density of 2.5 x 106 cells in 20 mM Hepes,
125 mMNaCl, 5 mM KCI, 1 mM CaCl, 1 mMMgCl, 0.5mM glucose, 0.025humanserum
albumin (Calbiochem-Behring Corp., LaJolla, CA), pH 7.4. The release experimentswere
performed in ashakingwaterbath at37"C andthereaction wasstopped byplacingthe tubes
in an ice bath, except for kinetic experimentswhere thecellswere rapidly cooled by adding
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1 vol of ice cold buffer. Histamine release is expressed as percent of the total cellular hista-
mine content minus the release in the buffer control sample. The total histamine content
in the different cell preparations ranged from 41 to 168 ng histamine per 2.5 x 10 6 cells .
Sulfidoleukotriene generation is expressed as picograms sulfidoleukotriene per nanogram total
cellular histamine. Each experiment was performed at least three times in triplicates .
Granule Releasefrom Human Neutrophils .
￿
The release of primary and secondary granules
in response to NAFINAP-l was assessed as described in detail (10) . The release experiments
were performed with 4 x 106 neutrophils per milliliter preincubated with 5 hg/ml cyto-
chalasin B (Sigma Chemical Co ., St . Louis, MO) for 5 min, and the reaction was stopped
in an ice bath 15 min after the addition ofthe stimulus . Granule marker release is expressed
as percent of the cellular content (determined from Triton X-100 lysed cells), minus the re-
lease in buffer controls .
Stimuli.
￿
Human rIL-3 (bioactivity of 106 U/1.5 mg) was a generous gift of Dr. M .
Schreier, Sandoz, Basel, Switzerland . 1 U/ml is defined as the concentration of IL-3 giving
a 50% of maximal [3H]TdR incorporation in cultures of leukocytes from chronic myeloid
leukemia patients . Human recombinant NAFINAP-1 from Escherichia coli had the same
neutrophil-activating potency as the natural product isolated from LPS-stimulated mononuclear
cells (11) . The peptides were stored at - 70°C and added to the cells in a 1 :100 volume ratio.
Results and Discussion
Histamine release from basophils in response to NAF/NAP-1 was studied in blood
mononuclear cells with and without pretreatment with IL-3, a pluripotent myeloid
cell growth factor (12, 13) that was recently found to enhance mediator release by
mature basophils in response to anti-IgE, FMLP, and C5a (9, 14) . As shown in Fig .
1, stimulation with 100 nM NAFINAP-l alone did not result in histamine release,
and in further experiments NAF/NAP-1 was equally ineffective in a concentration
range of 1 to 1,000 nM . Thus NAF/NAP-1 differs from the chemotactic peptides
C5aand FMLP, which induce basophil degranulation in a concentration-dependent
manner (1, 2, 9) . IL-3 alone also failed to induce histamine release at 20 ng/ml (Fig .
1) or at concentrations up to 1,000 ng/ml, which is consistent with former observa-
tions (9, 14) . In contrast, when the cells were exposed to IL-3 (20 ng/ml) and then
stimulated with NAFINAP-l (100 nM), amarked release ofhistamine corresponding
to -30% of the cellular content was regularly observed . The situation was similar
when production of LTC4 was determined . Basophils pretreated with 20 ng/ml IL-3
released on average 2.3 t 0.47 pg (SEM ; n = 24) LTC4 per nanogram of cellular
histamineupon stimulation with 100nM NARNAP-1, whereas no sulfidoleukotriene
production was detected after addition ofeither peptide alone, even at 10-fold higher
FIGURE 1 .
￿
Histamine release by human blood basophils .
The cells were treated with 20 ng/ml IL-3 for 25 min (IL-3,
circles) ; 100nM NAF/NAP-1 for 20 min (NAF, triangles) ; or
20 ng/ml IL-3 for 5 min followed by 100 nM NAFINAP-l
for 20 min (IL-3 + NAF, squares) . 24 determinations with
cells from 8 different donors are shown .concentrations. Although significant, the amount of LTC4 released upon stimula-
tion with NAF/NAP-1 was only 5-1010 /o of that obtained after optimal IgE receptor
crosslinking (1) or sequential treatment of basophils with IL-3 and C5a (9). It is
known, however, that LTC4 is ti1,000 times more potent than histamine on most
target tissues (15), suggesting that the amountsof leukotrienes released by NAF/NAP-
1-stimulated cells are sufficient to exert biological effects.
The induction of NAF/NAP-1 responsiveness by IL-3 was a rapid process. Some
histamine release was apparent when IL-3 and NAF/NAP-1 were added together,
but the maximal responsiveness to NAF/NAP-1 was observed when the cells were
pretreated which IL-3 for 5 min (data not shown). Thus, the time required for IL-
3-induced NAF/NAP-1 responsiveness was identical to that shown to be optimal for
an enhanced degranulation response of basophils stimulated with C5a (9).
The effect of IL-3 was concentration dependent with a threshold between 0.1 and
1 ng/ml (Fig. 2). The response of IL-3-pretreated basophils to different concentra-
tions of NAF/NAP-1 is illustrated in Fig. 3a. Histamine and sulfidoleukotriene re-
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FIGURE 2.
￿
Effect of the IL-3 concentration on the
NAF/NAP-1-induced basophil activation. The cells
were exposedto IL-3 for5 minand then stimulated
with 100nM NAF/NAP-1for20 min. Histaminere-
lease(circles) and sulfidoleukotriene generation (tri-
angles). The lowest value ofthe right hand ordinate
indicates the detectionlimit forsulfidoleukotrienes.
Mean values oftriplicates from arepresentative ex-
periment.
FIGURE 3.
￿
Activation ofbasophils(a) andneutrophils
(b)by NAF/NAP-1. Dependence on the NAF/NAP-1 con-
centration. (a)Histaminerelease (circles) andgeneration
ofsulfidoleukotrienes (triangles) by basophilstreated for
5 minwith 20 ng/ml IL-3 and then stimulated with the
indicatedconcentrations of NAF/NAP-1. (b)Release of
fl-glucuronidase from primary granules (circles) and
vitamin B12-binding protein from secondary granules
(triangles) inducedby NAF/NAP-1 in humanneutrophils.
Percent oftotalcellular content released minusthevalues
in unstimulated controls. Mean values of triplicate de-
terminations.1790
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lease increased progressively with the concentration of NANNAP-1 between 1 and
1,000nM. For comparison, thewell-established effects of NAP/NAP-1 on the release
of neutrophil granule constituents were examined in parallel experiments (Fig. 3
b). These results show that IL-3-pretreated basophils are activated by NAF/NAP-1
in a similar concentration range as neutrophils. In additional experiments it was
found that agonist-induced exocytosis of azurophil and specific granules in human
neutrophils was not influenced by IL-3 (not shown). The time course of the release
response of basophils induced by NAF/NAP-1 is shown in Fig. 4. Histamine and
sulfidoleukotrienes were released rapidly, the maximum being reached within 5-10
min of stimulus addition.
NAF/NAP-1 is known to activate and attract neutrophils in vitro and to induce
aneutrophilic cellular infiltration in vivo (5-8). Except forthe reported chemotactic
activity towardsTlymphocytes (16), NAF/NAP-1 appeared to be aselective stimulus
for neutrophils, since in contrast to other neutrophil agonists like C5a and FMLP,
it does not activate monocytes or eosinophils (8, 17). We now show that upon treat-
ment with IL-3, NAF/NAP-1 also triggers basophils to releasehistamineandsulfidoleu-
kotrienes, mediators that canpromote vascular leakage, smooth muscle contraction
and mucus formation. Thus, in the presence of IL-3, NAF/NAP-1 functions like
a "histamine-releasing factor" and may provoke symptoms of hypersensitivity reac-
tions and induce edema.
IL-3 has been recently shown to enhance degranulation of basophils stimulated
with anti-IgE, FMLP, andC5a(9, 14) and to change themediator profileofbasophils
triggered by C5a(9). The presentstudydemonstrates that IL-3 also hasthe capacity
to render basophils responsive to NAF/NAP-1. It is well established that IL-3 is a
product of T lymphocytes (12). Furthermore, IL-3 and NAF/NAP-1 are likely to
be co-produced at sites of inflammation, since IL-3 (in addition to other cytokines)
induces NAF/NAP-1 formation in monocytes (our unpublished observation). Thus,
30
ae
20
m
S m
m c
10
m
t
m
E
t
a
M u c 2
O Y
5
a
3
2
0 5 10 15 20
Time(min)
FIGURE 4.
￿
Time-course ofproduct releaseby NAF/NAP-
1-stimulated basophils. Cellswere pretreated with 20 ng/ml
IL-3 for5 min and then stimulated with 100 TIM NAP-1.
Histamine and sulfidoleukotriene releasewas determined
at different timesafterNAF/NAP-1 addition. Mean values
t SEM from nine separate assays.DAHINDEN ET AL.
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NARNAP-1-dependent basophil degranulaton mayoccurin pathological conditions
associated with T cell activation.
On the other hand, it has been shown recently that cultured murine mast cells
releaseIL-3 after IgE receptor crosslinking (18, 19), suggesting that basophil activa-
tion by IL-3 and NAF/NAP-1 may also ensue from IgE-dependent events. It is in-
teresting that immediately after antigen challenge of allergic individuals, the mast
cell mediators histamine, proteases, sulfidoleukotrienes, and prostaglandin D2 are
detected in nasalwashes. In so called late-phase reactions, whichoccurseveralhours
after allergen challenge, a second peak of the same mediators was measured, but
prostaglandin D2 was lacking (20). From these observations it has been suggested
that basophils are a major effector cell type in allergic late-phase reactions, since
basophils are incapable of producing prostaglandin D2 and since basophils are
present in cellular infiltrates of late-phase reactions (20). Thus, basophil activation
as described here could also be involved in the pathogenesis of allergic late-phase
reactions, which are thought to be responsible for the major symptoms in clinical
allergy.
Summary
IgE-independentmediator release from basophils is considered an importantevent
in inflammation, particularly in nonallergic immediate hypersensitivity and in al-
lergic late-phase reactions. This study demonstrates that after exposure to IL-3,
basophils release histamine and leukotrienes in response to the neutrophil-activating
peptide NAF/NAP-1. Thus, thesequential action oftwo pure cytokines can promote
basophils mediator release. In the presence of IL-3, NAF/NAP-1 functions like a
"histamine-releasing factor" and may therefore not only induce cellular infiltration
but also provoke symptoms of hypersensitivity reactions.
Receivedfor publication 5July 1989 and in revisedform 10 August 1989.
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